An Integrative Genomic Strategy Identifies Soluble Receptor for Advanced Glycation End-Products as a Causal and Protective Biomarker of Lung Function

Chest. 2022 Jan;161(1):3-5. doi: 10.1016/j.chest.2021.08.005.

Authors

Valerie R Wiersma¹, Simon D Pouwels²

Affiliations

¹ Department of Hematology, Cancer Research Center Groningen, Groningen, The Netherlands.
² Departments of Pathology and Medical Biology and Pulmonary Diseases, Groningen, The Netherlands; Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: s.d.pouwels@umcg.nl.

PMID: 35000706
DOI: 10.1016/j.chest.2021.08.005

No abstract available

Publication types

Editorial
Comment

MeSH terms

Biomarkers
Genomics*
Glycation End Products, Advanced*
Humans
Lung
Receptor for Advanced Glycation End Products / genetics

Substances

Biomarkers
Glycation End Products, Advanced
Receptor for Advanced Glycation End Products